- Title
- International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL
- Creator
- Awan, Farrukh T.; Addison, Daniel; Tam, Constantine; Ysebaert, Loïc; Alfraih, Feras; Baratta, Sergio J.; Campos, Rodrigo Noronha; Cugliari, María Silvana; Goh, Yeow Tee; Ionin, Valery Alexandrovich; Mundnich, Stefanie; Sverdlov, Aaron L.
- Relation
- Blood Advances Vol. 6, Issue 18, p. 5516-5525
- Publisher Link
- http://dx.doi.org/10.1182/bloodadvances.2022007938.
- Publisher
- American Society of Hematology (ASH)
- Resource Type
- journal article
- Date
- 2022
- Description
- Bruton’s tyrosine kinase inhibitors (BTKis) have altered the treatment landscape for chronic lymphocytic leukemia (CLL) by offering effective and well-tolerated therapeutic options. However, since the approval of ibrutinib, concern has risen regarding the risk of cardiovascular (CV) adverse events, including atrial fibrillation (AF), hypertension, and heart failure. Newer BTKis appear to have lower CV risks, but data are limited. It is important to understand the risks posed by BTKis and how those risks interact with individual patients, and we convened a panel of physicians with expertise in CLL and CV toxicities in oncology to develop evidence-based consensus recommendations for community hematologists and oncologists. Care providers should thoroughly assess a patient’s CV risk level before treatment initiation, including established CV diseases and risk factors, and perform investigations dependent on preexisting diseases and risk factors, including an electrocardiogram (ECG). For patients with high CV risk, BTKi treatment is often appropriate in consultation with a multidisciplinary team (MDT), and more selective BTKis, including acalabrutinib and zanubrutinib, are preferred. BTKi treatment should generally be avoided in patients with a history of heart failure. Ibrutinib should be avoided in patients with a history of ventricular arrhythmias, but the risk of newer drugs is not yet known. Finally, an MDT is crucial to help manage emerging toxicities with the goal of maintaining BTKi therapy, if possible. Optimizing heart failure, arrhythmia, and hypertension control will likely improve tolerance and maintenance of BTKi therapy. However, additional studies are needed to identify the most optimal strategy for these drugs.
- Subject
- health services and outcomes; lymphoid neoplasia; review article; Bruton’s tyrosine kinase inhibitors; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1489656
- Identifier
- uon:52741
- Identifier
- ISSN:2473-9529
- Language
- eng
- Reviewed
- Hits: 1405
- Visitors: 1370
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|